Mark Miglarese

Title: Mark Miglarese: Innovator in Lung Cancer Subtyping

Introduction

Mark Miglarese is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of cancer research, particularly in the molecular subtyping of lung cancer. His innovative methods have the potential to improve patient outcomes by providing more accurate diagnoses.

Latest Patents

Mark Miglarese holds a patent titled "Methods for typing of lung cancer." This patent outlines methods and compositions for the molecular subtyping of lung cancer samples. Specifically, it provides a method for assessing whether a patient's lung cancer subtype is adenocarcinoma, squamous cell carcinoma, or neuroendocrine, which includes both small cell carcinoma and carcinoid. The methods involve probing the levels of classifier biomarkers at the nucleic acid level in lung cancer samples obtained from patients. Based on these levels, the lung cancer sample can be classified into a specific subtype.

Career Highlights

Throughout his career, Mark has worked with prominent organizations such as GeneCentric Therapeutics, Inc. and the University of North Carolina at Chapel Hill. His work in these institutions has allowed him to collaborate with leading experts in the field of cancer research.

Collaborations

Mark has collaborated with notable colleagues, including Gregory Mayhew and Charles M Perou. These partnerships have furthered his research and contributed to advancements in lung cancer diagnostics.

Conclusion

Mark Miglarese's innovative work in lung cancer subtyping exemplifies the impact of research on patient care. His contributions are paving the way for more precise and effective cancer treatments.